Clinical trials: Psoriasis Vulgaris
Psoriasis Vulgaris
Improvement of Psoriasis Patients' Adherence to Topical Drugs
Psoriasis affects 2-4% of the Western adult population and is a socio-economic burden for patients and society. Topical drugs are recommended as first-line treatment for mild-to-moderate psoriasis, but low adherence is a barrier…
- Trial name
- NCT04220554
- Testing
- Improved support by health-care professionals
- Where
- Denmark
- Volunteers
- 103 people
- Sponsor
- Odense University Hospital
Psoriasis Vulgaris
Adjusted Brodalumab Dose Compared With Standard Brodalumab Dose in Subjects With Moderate-to-severe Plaque Psoriasis and ≥120 kg Body Weight
This study investigates if an adjusted brodalumab dosage regimen will give improved efficacy in psoriasis in patients with a body weight of over 120 kg.
- Trial name
- ADJUST (NCT04306315)
- Testing
- Brodalumab
- Where
- 81 sites in Belgium, Czechia and 9 more
- Volunteers
- 385 people
- Sponsor
- LEO Pharma
Acne, Atopic Dermatitis
Collection of Samples From Subjects With Various Skin Conditions and Healthy Volunteers
The purpose of the study is to collect different samples for molecular characterization of inflammatory skin diseases.
- Conditions
- Acne, Atopic Dermatitis, Chronic Hand Eczema, Hidradenitis Suppurativa
- Trial name
- NCT05994976
- Testing
- Blood samples collection, Oral samples collection, Hair samples collection
- Where
- Canada
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Innovaderm Research Inc.
Psoriasis Vulgaris
LEO 80185 in the Treatment of Psoriasis Vulgaris on the Non-scalp Regions of the Body (Trunk and/or Limbs)
The purpose of this study is to compare the efficacy and safety of Calcipotriol 50 Mcg/g Plus Betamethasone 0.5 mg/g (as Dipropionate) Topical Suspension with the active components when used individually as monotherapy in the…
- Trial name
- NCT01188928
- Testing
- Calcipotriol plus betamethasone, Betamethasone-17,21-dipropionate, Calcipotriene
- Where
- 59 sites in United States
- Volunteers
- 1,152 people
- Sponsor
- LEO Pharma
Psoriasis Vulgaris
Efficacy and Safety of Blue Light (453 nm) Treatment for Mild Psoriasis Vulgaris Over Three Months Compared to Vitamin D.
Patients will be screened up to 28 days before start of treatment. During the screening visit, the purpose and procedures of the study will be explained to potential patients and informed consent will be obtained.
- Trial name
- NCT02735187
- Testing
- Blue light treatment, Vitamin D
- Where
- Germany
- Volunteers
- 51 people
- Sponsor
- Philips Electronics Nederland BV
Psoriasis Vulgaris, Psoriatic Arthritis
Impact of Decision-Framing in Psoriasis
Rationale: Shared decision-making models between clinicians and patients are critical to improving healthcare delivery and adherence to medication. One type of model, decision framing, is rarely studied in medicine.
- Conditions
- Psoriasis Vulgaris, Psoriatic Arthritis, Psoriasis
- Trial name
- NCT04136314
- Testing
- Decision-Framed Survey
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- University of Southern California
Psoriasis, Psoriasis Vulgaris
Biofeedback for Psoriasis
We are conducting a proof-of-concept trial to study the impact of HRV-biofeedback, a mind-body technique designed to improve stress resilience, on the quality of life, mood, and clinical skin severity of patients with psoriasis.
- Conditions
- Psoriasis, Psoriasis Vulgaris, Psychophysiological Disorder, Anxiety
- Trial name
- NCT05506644
- Testing
- HRV-Biofeedback/Mind-Body Therapy
- Where
- United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Bastyr University
Moderate to Severe Chronic Plaque Psoriasis
A Study to Evaluate the Safety and Effectiveness of Doxercalciferol Capsules in Participants With Moderate to Severe Psoriasis
The purpose of this study was to evaluate the safety and effectiveness of an investigational drug called doxercalciferol in participants with moderate to severe chronic plaque psoriasis, in comparison with a placebo ("sugar…
- Trial name
- NCT00601107
- Testing
- Doxercalciferol
- Where
- 19 sites in United States
- Volunteers
- 111 people
- Sponsor
- Genzyme, a Sanofi Company
Psoriasis Vulgaris
Therapeutic Drug Monitoring of Tildrakizumab in Psoriasis Patients
Biologics such as tildrakizumab are currently the most effective treatment option for patients with moderate to severe psoriasis.
- Trial name
- BIOLOPTIM-TIL (NCT05683015)
- Testing
- Venapuncture, Patient questionnaires
- Where
- 2 sites in Belgium
- Volunteers
- 100 people
- Sponsor
- University Hospital, Ghent
Psoriasis Vulgaris
A 12 Day Study To Evaluate A Topical Drug To Treat Plaque Psoriasis
This is a vehicle and comparator controlled Proof of Mechanism (PoM) trial to evaluate the effect on psoriasis disease activity and safety of topically applied PF 06263276 in subjects with psoriasis vulgaris.
- Trial name
- NCT02193815
- Testing
- PF06263276, Vehicle, 2%Tofacitinib Ointment
- Where
- Germany
- Volunteers
- 15 people
- Sponsor
- Pfizer
Psoriasis Vulgaris
Dosage Determination Trial for Indigo Naturalis Extract in Oil Ointment
The use of refined indigo naturalis (indigo naturalis extract in oil, INEO)ointment to treat psoriasis has been proven effective in our previous study.
- Trial name
- NCT01735864
- Testing
- Indirubin 200μg/g, Indirubin 100 μg/g, Indirubin 50 μg/g
- Where
- 3 sites in Taiwan
- Volunteers
- 100 people
- Sponsor
- Chang Gung Memorial Hospital
Psoriasis, Psoriasis Palmaris
Systemic Treatment of Moderate-to-severe Psoriasis in Adults: Update of the French Guidelines
French guidelines on the use of systemic treatments for moderate-to-severe psoriasis in adults have been developed by the psoriasis research group of the French Society of Dermatology using literature available until July 2017…
- Conditions
- Psoriasis, Psoriasis Palmaris, Psoriasis Inverse, Psoriasis Vulgaris
- Trial name
- NCT05144165
- Testing
- Experts consensus
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Centre of Evidence of the French Society of Dermatology
Psoriasis Vulgaris, Active Psoriatic Arthritis
Effect of Bimekizumab in Patients With Psoriasis Vulgaris and Active Psoriatic Arthritis
This is an open-label study to evaluate the effects of bimekizumab in patients with psoriasis vulgaris and who also have active psoriatic arthritis (PsA).
- Trial name
- NCT05499416
- Testing
- Bimekizumab
- Sponsor
- Innovaderm Research Inc.
Psoriasis
LEO 90105 Ointment in Japanese Subjects With Psoriasis
The purpose of this study is to compare the efficacy of LEO 90105 ointment applied once daily with Dovonex® ointment applied twice daily and with Rinderon®-DP ointment applied once daily in Japanese subjects with psoriasis…
- Trial name
- NCT01422434
- Testing
- LEO 90105 = calcipotriol + betamethasone dipropionate, Dovonex® = calcipotriol, Rinderon® - DP = betamethasone dipropionate
- Where
- Japan
- Volunteers
- 676 people
- Sponsor
- LEO Pharma
Psoriasis
A Study of Ixekizumab in Chinese Participants With Psoriasis Vulgaris
The purpose of the study is to research how much ixekizumab enters the bloodstream and how long the body takes to get rid of the drug and the safety of ixekizumab and any side effects that might be associated with it.
- Trial name
- NCT03073213
- Testing
- Ixekizumab
- Where
- 3 sites in China
- Volunteers
- 32 people
- Sponsor
- Eli Lilly and Company
Psoriasis Vulgaris
Pharmacogenomics Study on Treatment of Psoriasis Vulgaris by Methotrexate
To investigate the influence of genetic factors on the curative effect , to find the relationships between genetic variants and the response of Methotrexate to treatment of Psoriasis Vulgaris.
- Trial name
- NCT02715947
- Testing
- Methotrexate
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Central South University
Psoriasis Vulgaris
LEO 90100 Compared to Vehicle in Subjects With Psoriasis Vulgaris
The purpose of this trial is to compare the efficacy of treatment with LEO 90100 to that of treatment with vehicle for up to 4 weeks in subjects with psoriasis vulgaris.
- Trial name
- NCT01866163
- Testing
- LEO 90100, Vehicle
- Where
- United States
- Volunteers
- 426 people
- Sponsor
- LEO Pharma
Psoriasis Vulgaris
Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel in Psoriasis Vulgaris
The objective of the study is to compare the use of calcipotriol plus betamethasone dipropionate gel with betamethasone dipropionate in the gel vehicle, calcipotriol in the gel vehicle and the gel vehicle alone when used in…
- Trial name
- NCT00263718
- Testing
- Calcipotriol plus betamethasone dipropionate (LEO 80185) gel
- Where
- 5 sites in Canada, Germany and 3 more
- Volunteers
- 360 people
- Sponsor
- LEO Pharma
Psoriasis
Excimer Laser With Topical Agents in Psoriasis Vulgaris
Psoriasis is a chronic, immune-mediated disease that affects approximately 2% of the population. The development and exacerbation of psoriasis involve an interaction between multiple genetic and environmental risk factors.
- Trial name
- NCT05555797
- Testing
- 308nm Excimer laser, Tazarotene Topical Gel, Betamethasone Valerate
- Volunteers
- 30 people
- Sponsor
- Assiut University
Psoriasis Vulgaris, Psoriasis Arthropathica
Infliximab Biosimilar for Intravenous Drip Infusion 100 mg "Pfizer" Drug Use Investigation (Psoriasis)
To collect information on the safety and effectiveness of Infliximab BS for Intravenous Drip Infusion 100 mg "Pfizer" against psoriasis vulgaris, psoriasis arthropathica, pustular psoriasis, or erythrodermic psoriasis under…
- Conditions
- Psoriasis Vulgaris, Psoriasis Arthropathica, Pustular Psoriasis, Erythrodermic Psoriasis
- Trial name
- NCT03885089
- Testing
- Infliximab [infliximab biosimilar 3]
- Where
- Japan
- Volunteers
- 10 people
- Sponsor
- Pfizer